Operaciones Quince Therapeuticks Inc - QNCX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.0328 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024874% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.002651% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 1.5486 |
Abrir* | 1.4886 |
Cambio de 1 año* | -75.76% |
Rango del día* | 1.4886 - 1.5586 |
Rango de 52 semanas | 0.54-6.80 |
Volumen medio (10 días) | 5.94M |
Volumen medio (3 meses) | 47.55M |
Capitalización de mercado | 55.87M |
Ratio P/E | -100.00K |
Acciones en circulación | 36.28M |
Ingresos | N/A |
EPS | -1.61 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.31 |
Próxima fecha de resultados | N/A |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 1.5486 | 0.0600 | 4.03% | 1.4886 | 1.5686 | 1.4886 |
Mar 30, 2023 | 1.5486 | 0.0500 | 3.34% | 1.4986 | 1.5686 | 1.4886 |
Mar 29, 2023 | 1.5386 | 0.0499 | 3.35% | 1.4887 | 1.5686 | 1.4687 |
Mar 28, 2023 | 1.4687 | 0.0100 | 0.69% | 1.4587 | 1.5186 | 1.4487 |
Mar 27, 2023 | 1.4487 | 0.0200 | 1.40% | 1.4287 | 1.5486 | 1.4287 |
Mar 24, 2023 | 1.4587 | 0.0600 | 4.29% | 1.3987 | 1.4787 | 1.3488 |
Mar 23, 2023 | 1.3588 | -0.0899 | -6.21% | 1.4487 | 1.4687 | 1.3488 |
Mar 22, 2023 | 1.4187 | 0.0200 | 1.43% | 1.3987 | 1.4687 | 1.3688 |
Mar 21, 2023 | 1.4187 | 0.0000 | 0.00% | 1.4187 | 1.5186 | 1.3388 |
Mar 20, 2023 | 0.8196 | 0.0004 | 0.05% | 0.8192 | 0.8360 | 0.7892 |
Mar 17, 2023 | 0.8188 | -0.0171 | -2.05% | 0.8359 | 0.8359 | 0.7848 |
Mar 16, 2023 | 0.8193 | -0.0066 | -0.80% | 0.8259 | 0.8557 | 0.7919 |
Mar 15, 2023 | 0.8410 | -0.0382 | -4.34% | 0.8792 | 0.8792 | 0.8155 |
Mar 14, 2023 | 0.8716 | -0.0339 | -3.74% | 0.9055 | 0.9155 | 0.8691 |
Mar 13, 2023 | 0.8791 | -0.0663 | -7.01% | 0.9454 | 0.9454 | 0.8656 |
Mar 10, 2023 | 0.9237 | -0.0326 | -3.41% | 0.9563 | 0.9752 | 0.9237 |
Mar 9, 2023 | 0.9743 | -0.0247 | -2.47% | 0.9990 | 1.0490 | 0.9643 |
Mar 8, 2023 | 0.9832 | 0.0080 | 0.82% | 0.9752 | 0.9950 | 0.9393 |
Mar 7, 2023 | 0.9591 | 0.0079 | 0.83% | 0.9512 | 0.9784 | 0.9491 |
Mar 6, 2023 | 0.9667 | 0.0023 | 0.24% | 0.9644 | 0.9868 | 0.9433 |
Quince Therapeuticks Inc Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 52.015 | 90.318 | 78.893 | 39.168 | 12.119 |
Gastos de venta/general/administración Gastos, total | 26.012 | 29.523 | 17.586 | 8.954 | 2.034 |
Investigación y desarrollo | 25.178 | 60.795 | 61.307 | 30.214 | 10.085 |
Ingresos de explotación | -52.015 | -90.318 | -78.893 | -39.168 | -12.119 |
Ingresos por intereses (gastos), netos No operativos | 1.068 | 0.62 | 2.044 | 2.188 | -0.357 |
Ingresos netos antes de impuestos | -51.944 | -89.945 | -76.849 | -36.98 | -12.476 |
Ingresos netos después de impuestos | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Beneficio neto antes de partidas extra. Elementos | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Total de partidas extraordinarias | |||||
Ingresos netos | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Beneficio neto diluido | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Promedio ponderado de acciones diluidas | 33.4965 | 29.7185 | 29.1762 | 19.0319 | 26.0133 |
BPA diluido sin partidas extraordinarias | -1.54225 | -3.02657 | -2.63396 | -1.94305 | -0.4796 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
BPA normalizado diluido | -1.52624 | -3.02657 | -2.63396 | -1.94305 | -0.4796 |
Otros, netos | -0.997 | -0.247 | |||
Gastos (ingresos) extraordinarios | 0.825 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 6.319 | 7.62 | 16.258 | 21.863 | 23.544 |
Gastos de venta/general/administración Gastos, total | 3.551 | 4.344 | 9.059 | 9.106 | 8.331 |
Investigación y desarrollo | 2.768 | 2.451 | 7.199 | 12.757 | 15.213 |
Ingresos de explotación | -6.319 | -7.62 | -16.258 | -21.863 | -23.544 |
Ingresos por intereses (gastos), netos No operativos | 0.536 | 0.315 | 0.145 | 0.072 | 0.105 |
Ingresos netos antes de impuestos | -5.534 | -7.921 | -16.848 | -21.641 | -23.399 |
Ingresos netos después de impuestos | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Beneficio neto antes de partidas extra. Elementos | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Ingresos netos | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Beneficio neto diluido | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Promedio ponderado de acciones diluidas | 35.7117 | 35.6128 | 32.467 | 30.1345 | 29.962 |
BPA diluido sin partidas extraordinarias | -0.15496 | -0.22242 | -0.51018 | -0.71815 | -0.78095 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
BPA normalizado diluido | -0.15496 | -0.19925 | -0.51018 | -0.71815 | -0.78095 |
Otros, netos | 0.249 | -0.616 | -0.735 | 0.15 | 0.04 |
Gastos (ingresos) extraordinarios | 0 | 0.825 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Activo Corriente | 111.673 | 137.862 | 106.056 | 72.584 | 7.537 |
Efectivo e inversiones a corto plazo | 106.802 | 133.82 | 99.864 | 71.716 | 7.343 |
Cash | 40.27 | 35.69 | 4.074 | 11.259 | 7.343 |
Efectivo y Equivalentes | 15.954 | 16.151 | 46.155 | 11.815 | 0 |
Inversiones a corto plazo | 50.578 | 81.979 | 49.635 | 48.642 | 0 |
Prepaid Expenses | 3.376 | 3.348 | 5.504 | 0.766 | 0.141 |
Other Current Assets, Total | 1.495 | 0.694 | 0.688 | 0.102 | 0.053 |
Total Assets | 133.228 | 189.466 | 124.37 | 72.877 | 7.718 |
Property/Plant/Equipment, Total - Net | 1.428 | 1.101 | 1.334 | 0.283 | 0.122 |
Property/Plant/Equipment, Total - Gross | 2.387 | 1.716 | 1.617 | 0.378 | 0.166 |
Accumulated Depreciation, Total | -0.959 | -0.615 | -0.283 | -0.095 | -0.044 |
Other Long Term Assets, Total | 0.194 | 0.039 | 0.217 | 0.01 | 0.059 |
Total Current Liabilities | 14.222 | 16.996 | 8.892 | 1.457 | 1.763 |
Accounts Payable | 4.911 | 3.555 | 3.075 | 0.495 | 0.517 |
Accrued Expenses | 9.311 | 13.441 | 5.817 | 0.962 | 1.246 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.642 | 17.204 | 8.892 | 1.457 | 10.82 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 7.171 |
Long Term Debt | 0 | 7.171 | |||
Other Liabilities, Total | 0.42 | 0.208 | 0 | 1.886 | |
Total Equity | 118.586 | 172.262 | 115.478 | 71.42 | -3.102 |
Redeemable Preferred Stock | 0 | 104.046 | 17.178 | ||
Common Stock | 0.03 | 0.029 | 0.027 | 0.009 | 0.009 |
Additional Paid-In Capital | 355.234 | 318.574 | 185.196 | 0.239 | 0.06 |
Retained Earnings (Accumulated Deficit) | -236.599 | -146.654 | -69.805 | -32.825 | -20.349 |
Other Equity, Total | -0.079 | 0.313 | 0.06 | -0.049 | 0 |
Total Liabilities & Shareholders’ Equity | 133.228 | 189.466 | 124.37 | 72.877 | 7.718 |
Total Common Shares Outstanding | 30.0744 | 29.5432 | 26.8694 | 26.0133 | 26.0133 |
Long Term Investments | 19.933 | 50.464 | 16.763 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 96.353 | 111.673 | 119.427 | 135.843 | 149.885 |
Efectivo e inversiones a corto plazo | 91.524 | 106.802 | 114.412 | 129.95 | 147.035 |
Cash | 27.403 | 40.27 | 8.357 | 5.744 | 24.569 |
Efectivo y Equivalentes | 32.361 | 15.954 | 36.6 | 47.049 | 38.246 |
Inversiones a corto plazo | 31.76 | 50.578 | 69.455 | 77.157 | 84.22 |
Prepaid Expenses | 2.784 | 3.376 | 4.52 | 5.455 | 2.293 |
Other Current Assets, Total | 2.045 | 1.495 | 0.495 | 0.438 | 0.557 |
Total Assets | 116.13 | 133.228 | 147.416 | 161.39 | 174.522 |
Property/Plant/Equipment, Total - Net | 0.573 | 1.428 | 1.655 | 1.886 | 0.878 |
Property/Plant/Equipment, Total - Gross | 1.569 | 2.387 | 2.53 | 2.674 | 1.579 |
Accumulated Depreciation, Total | -0.996 | -0.959 | -0.875 | -0.788 | -0.701 |
Long Term Investments | 19.175 | 19.933 | 26.141 | 23.516 | 23.72 |
Other Long Term Assets, Total | 0.029 | 0.194 | 0.193 | 0.145 | 0.039 |
Total Current Liabilities | 9.71 | 14.222 | 14.154 | 18.537 | 17.867 |
Accounts Payable | 3.731 | 4.911 | 2.88 | 7.193 | 2.845 |
Accrued Expenses | 5.979 | 9.311 | 11.274 | 11.344 | 15.022 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9.75 | 14.642 | 14.764 | 19.31 | 18.038 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.04 | 0.42 | 0.61 | 0.773 | 0.171 |
Total Equity | 106.38 | 118.586 | 132.652 | 142.08 | 156.484 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.029 |
Additional Paid-In Capital | 365.096 | 355.234 | 345.751 | 333.427 | 326.006 |
Retained Earnings (Accumulated Deficit) | -258.24 | -236.599 | -213.2 | -191.494 | -169.74 |
Other Equity, Total | -0.506 | -0.079 | 0.071 | 0.117 | 0.189 |
Total Liabilities & Shareholders’ Equity | 116.13 | 133.228 | 147.416 | 161.39 | 174.522 |
Total Common Shares Outstanding | 30.1496 | 30.0744 | 29.8673 | 29.6558 | 29.5759 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -89.945 | -76.849 | -36.98 | -12.476 | -12.235 |
Efectivo de actividades de explotación | -62.932 | -50.818 | -33.277 | -11.695 | -9.827 |
Efectivo de actividades de explotación | 0.344 | 0.332 | 0.188 | 0.051 | 0.045 |
Partidas no monetarias | 30.93 | 15.472 | 1.611 | 1.12 | 1.903 |
Intereses pagados en efectivo | 0.001 | 0.001 | |||
Cambios en el capital circulante | -4.261 | 10.227 | 1.904 | -0.39 | 0.46 |
Efectivo de actividades de inversión | 58.952 | -52.431 | -17.747 | -46.754 | -0.077 |
Gastos de capital | -0.18 | -0.052 | -0.055 | -0.212 | -0.077 |
Otras partidas de flujo de caja de inversión, total | 59.132 | -52.379 | -17.692 | -46.542 | 0 |
Efectivo procedente de actividades de financiación | 6.808 | 118.876 | 77.366 | 75.928 | 7.75 |
Emisión (retiro) de acciones, neto | 6.808 | 118.91 | 77.925 | 75.678 | 0 |
Emisión (amortización) de deuda, neta | 0 | -0.034 | -0.559 | 0.25 | 7.75 |
Variación neta de la tesorería | 2.883 | 15.627 | 26.342 | 17.479 | -2.154 |
Efectos del cambio de divisas | 0.055 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -21.641 | -89.945 | -66.546 | -44.84 | -23.086 |
Cash From Operating Activities | -16.091 | -62.932 | -48.514 | -31.172 | -13.61 |
Cash From Operating Activities | 0.038 | 0.344 | 0.26 | 0.173 | 0.086 |
Non-Cash Items | 9.375 | 30.93 | 22.238 | 14.371 | 7.285 |
Changes in Working Capital | -3.863 | -4.261 | -4.466 | -0.876 | 2.105 |
Cash From Investing Activities | 13.413 | 58.952 | 38.033 | 37.267 | 31.643 |
Capital Expenditures | -0.005 | -0.18 | -0.136 | -0.136 | -0.037 |
Other Investing Cash Flow Items, Total | 13.418 | 59.132 | 38.169 | 37.403 | 31.68 |
Cash From Financing Activities | 0.622 | 6.808 | 5.818 | 1.113 | 0.441 |
Issuance (Retirement) of Stock, Net | 0.622 | 6.808 | 5.818 | 1.113 | 0.441 |
Net Change in Cash | -2.16 | 2.883 | -4.634 | 7.208 | 18.474 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Foreign Exchange Effects | -0.104 | 0.055 | 0.029 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Lamond (David A.) | Individual Investor | 10.1543 | 3683658 | 1634720 | 2022-01-31 | |
Dominy (Stephen S) | Individual Investor | 3.9631 | 1437674 | 763 | 2022-01-31 | |
Lynch (Casey C) | Individual Investor | 3.2544 | 1180580 | -120000 | 2022-01-31 | |
EPIQ Capital Group, LLC | Investment Advisor | 2.9115 | 1056191 | -1000478 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 2.4701 | 896084 | -61145 | 2022-12-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.3524 | 853391 | -18615 | 2022-12-31 | LOW |
Pfizer Inc | Corporation | 1.6539 | 600000 | -1456377 | 2021-12-31 | MED |
Millennium Management LLC | Hedge Fund | 1.6424 | 595801 | 137810 | 2022-12-31 | HIGH |
Low (Philip S) | Individual Investor | 1.2551 | 455309 | 455309 | 2022-05-19 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9169 | 332627 | -165208 | 2022-12-31 | LOW |
Thye (Dirk) | Individual Investor | 0.7744 | 280911 | 280911 | 2022-05-19 | |
Lowe (Christopher P) | Individual Investor | 0.7305 | 265000 | 175000 | 2022-03-03 | LOW |
Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 0.6904 | 250458 | -264583 | 2022-12-31 | HIGH |
Smith (Karen L) | Individual Investor | 0.5367 | 194690 | 194690 | 2022-05-19 | LOW |
Alphabet, Inc. | Venture Capital | 0.5213 | 189122 | 0 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4248 | 154100 | -180125 | 2022-12-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.4239 | 153788 | 0 | 2022-12-31 | MED |
Holsinger (Leslie) | Individual Investor | 0.3985 | 144580 | -10920 | 2022-06-06 | |
Detke (Michael J) | Individual Investor | 0.3859 | 140000 | 140000 | 2022-03-03 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3779 | 137086 | -9128 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cortexyme Inc. Company profile
Sobre Cortexyme Inc
Cortexyme, Inc. es una empresa biofarmacéutica en fase clínica que se centra en proporcionar terapias modificadoras de la enfermedad para tratar el Alzheimer y otras enfermedades degenerativas. La empresa ofrece un inhibidor de 3CLpro, el producto COR803, que es un compuesto principal para el tratamiento de las infecciones por coronavirus. La cartera de productos de la empresa incluye candidatos a fármacos para el tratamiento de trastornos del sistema nervioso central (SNC), incluida la enfermedad de Alzheimer; para el tratamiento de aplicaciones oncológicas, incluida la prevención del carcinoma oral de células escamosas, y para el tratamiento de afecciones crónicas y desatendidas, como la periodontitis. El COR388 de la empresa es para el tratamiento de la enfermedad de Alzheimer y la enfermedad de Parkinson. El COR588 de la empresa está en fase I de ensayo clínico y su objetivo es utilizarlo en el tratamiento de la enfermedad periodontal y otras indicaciones relacionadas con la P. gingivalis. La empresa también está desarrollando el COR588, un inhibidor de la lisina gingipain de segunda generación que penetra en el cerebro.
Industry: | Biotechnology & Medical Research (NEC) |
269 East Grand Ave
94080
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com